ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with...

Related Keywords

United States ,Vancouver ,British Columbia ,Canada ,California ,San Francisco ,Canadian ,Peter Virsik ,David Parkinson ,University Of Wisconsin ,Pharma Inc ,Drug Administration ,Linkedin ,Twitter ,Madison Carbone Cancer Center ,Presents Updated Phase ,Clinical Data ,Cancers Symposium ,Christos Kyriakopoulos ,Wisconsin Madison Carbone Cancer ,Fast Track ,Private Securities Litigation Reform Act ,Chief Operating ,